바이오 신약 개발 기술과 응용

• Published in: Biomaterials research pp. 123 - 131
• Main Authors: 이준우, 표석능, 손은화, 유재영
• Format: Journal Article
• Language: Korean
• Published: 한국생체재료학회 01.09.2005
• Subjects: 의공학
• ISSN: 1226-4601; 2055-7124

Global biopharmaceutical sales are expected to increase by 5% p.a. over the next five years approaching US$20 billion by 2004. Biopharmaceuticals include recombinant proteins, genetically engineered vaccines; therapeutic monoclonal antibodies; and nucleic acid based therapeutics, including gene therapy vectors. The information from genomic, proteomic and metabolomic measurements has already benefited target discovery and validation, assessment of efficacy and toxicity of compounds, identification of disease subgroups and the prediction of responses of individual patients. Greater benefits can be expected from the application of these technologies on a significantly larger scale; by simultaneously collecting diverse measurements from the same subjects or cell cultures; by exploiting the steadily improving quantitative accuracy of the technologies; and by interpreting the emerging data in the context of underlying biological models of increasing sophistication. In this paper, we outline the introduction about biopharmaceutical drug design and development including some definitions, a brief history of the field, and a look at the biotechnology industry, regulatory challenges, ethical issues. This paper also provides the current trends in biopharmaceutical drug divelopment. Moreover, we discuss the basic element technology of new drug discovery including nucleic acids, DNA, RNA, proteins, and gene expression in detail. We analyze the current research insight of biopharmaceutical drugs and their market trends. In addition, the present paper discusses more detail about biopharmaceutical drug development focusing on the development of bioartificial organs inculding cardiovascular system, cancer, central nervous system, respiratory system, metabolitic system, immune system and therapeutic vaccines. KCI Citation Count: 0